✦ LIBER ✦

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors

✍ Scribed by Gautam Borthakur; Susan O'Brien; William G. Wierda; Deborah A. Thomas; Jorge E. Cortes; Francis J. Giles; Hagop M. Kantarjian; Susan Lerner; Michael J. Keating

Book ID: 108674165
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 496 KB
Volume: 136
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2007.06513.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fludarabine, Cyclophosphamide and Rituxi

Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia

✍ A. Hayat; S. McGuckin; E. Conneally; P. V. Brown; S. R. McCann; M. Lawler; F. Qu 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 174 KB

A randomized phase II trial of fludarabi

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

✍ Peter Hillmen; Dena R. Cohen; Kim Cocks; Andrew Pettitt; Hazem A. Sayala; Andy C 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Cerebral toxoplasmosis in a patient with

Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine

✍ S. Bacchu; C. Fegan; J. Neal 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

The Addition of Rituximab to Fludarabine

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

✍ Amit Mahipal; Mark Weiss 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 80 KB

Circulating CD52 and CD20 levels at end

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

✍ Gheath Alatrash; Maher Albitar; Susan O’Brien; Xuemei Wang; Taghi Manshouri; Ste 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Pentostatin, cyclophosphamide, and ritux

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

✍ Tait D. Shanafelt; Thomas Lin; Susan M. Geyer; Clive S. Zent; Nelson Leung; Bria 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## BACKGROUND. The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients ≥70 years of age. ## METHODS. Sixty‐four